ArticleFrontiers in molecular biosciences2026
Integrative multi-omics characterization of KLRB1/CD161 in diffuse large B-cell lymphoma: associations with immune context, subtype biology, and therapeutic response.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The tumor immune microenvironment (TME) of diffuse large B-cell lymphoma (DLBCL) displays pronounced heterogeneity, and existing immunotherapeutic approaches achieve only suboptimal outcomes for a considerable proportion of affected individuals. CD161-a C-type lectin receptor whose coding gene is KLRB1-has lately emerged as a modulator of T-cell activity in several malignancies; nonetheless, a thorough characterization of its function in DLBCL has not yet been undertaken. Methods: Transcriptomic analyses quantified KLRB1 mRNA, whereas flow cytometry and immunoblotting assessed its encoded surface protein, CD161. Transcriptomic, genomic, epigenomic (methylation), and exploratory single-cell RNA-sequencing datasets from DLBCL cohorts were integrated with Results: Pan-cancer analysis revealed predominantly inverse associations between KLRB1 mRNA and immunomodulatory features, whereas DLBCL bulk-tumor analyses showed positive correlations with MHC molecules, immune-cell infiltration estimates, CD8 Conclusion: The KLRB1 mRNA/CD161 protein axis is associated with an immune-inflamed DLBCL phenotype and ABC subtype biology. Its prognostic and treatment-predictive value remains hypothesis-generating and requires validation in multivariable survival models, DLBCL-specific immunotherapy cohorts, additional cell lines, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.